Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare, shared a post on X:
“TQB2450-III-12
Benmelstobart plus chemo – benmelstobart plus anlotinib vs Tislelizumab plus chemo in 1L sq-NSCLC shows:
Median PFS: 10.1 vs 7.8 mo (HR 0.64, p=0.0038)
ORR: 72% vs 65%
Benefit consistent across subgroups (PD-L1 1–49%, ECOG 0, age <65)
Manageable safety
Promising new 1L option.”
More posts featuring Diego A. Díaz García.